So we’re very proud of the results of the EMBARK analysis, a 10-plus year study looking at patients with high-risk BCR, post-RP, RRP, or both. And what we presented as a poster at ASCO GU this year was the patients who had PSAs of less than 0.2, and particularly those patients and the durability of how long they could remain off therapy. So a treatment interruption was what some folks would call a holiday...
So we’re very proud of the results of the EMBARK analysis, a 10-plus year study looking at patients with high-risk BCR, post-RP, RRP, or both. And what we presented as a poster at ASCO GU this year was the patients who had PSAs of less than 0.2, and particularly those patients and the durability of how long they could remain off therapy. So a treatment interruption was what some folks would call a holiday. And about 1 in 25 patients had greater than a two-year experience in the combination arm, which is not insignificant that patients can enjoy that level of a PSA declination and getting back to eugonadal levels of testosterone. So the added quality of life benefits that one would imagine with that. We saw lower percentages in the single-digit percentage with monotherapy ADT as well as with the monotherapy ARPI. But yet there were patients at one year, low single digit percentages, those become less. But we do find these patients who have sort of a super responder effect or outcome that can last not just one year, but sometimes two and three years. So it’s clearly a smaller subset of patients, but I think when you have those patients, it’s quite an impressive thing to observe.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
